Construction of the lncRNAs risk model and identification of GBM subtypes under immune environment, suggesting that KRT8, NGFR, TCEA3, and irlncRNAs had promising potential for clinical immunotherapy of GBM. Here, TCEA3 is linked to glioblastoma.